PLEASANTON, Calif., Feb. 16 /PRNewswire/ -- QuantaLife, Inc., a company developing breakthrough microfluidic technology and proprietary chemistry for nucleic acid testing applications that are relevant across many sectors, today announced that it was unanimously selected for the "Most Promising Company" award at the Personalized Medicine World Conference (PMWC) 2010, held January 19-20, 2010. The PMWC 2010 was created to examine the emerging field of personalized medicine, which can create a higher probability of desired outcomes thanks to better-targeted therapies, and helps focus on prevention and prediction of disease rather than simply reacting to it. QuantaLife was selected as the "Most Promising Company" on the basis of market need and enthusiasm for innovative products, barriers to competition, management team strength, "go-to market" strategy, and clear financial projections.
QuantaLife's recognition as the Most Promising Company at this year's PMWC further validates the clinical utility potential of the Company's revolutionary droplet digital PCR™ (ddPCR™) technology as a platform for well-resolved quantitation of important biomolecules. Seventeen companies presented at the PMWC 2010, many of whom have already achieved market clearance for their personalized medicine products. At the conference, QuantaLife executives demonstrated the growing need for a platform that validates digital biology discoveries that are enabled by next generation sequencing and microarray platforms. QuantaLife's strategy, illustrating ddPCR translation of digital biology discoveries into reliable, cost-effective diagnostic and prognostic products, was the unanimous choice for the award as judged by successful venture capital investors from Draper Fisher Jurvetson, Telegraph Hill Partners, Mohr-Davidow Ventures, and the Silicom Ventures an
|SOURCE QuantaLife, Inc.|
Copyright©2010 PR Newswire.
All rights reserved